We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Crowdfunding Opportunities


Probe Technology EIS
Probe has developed microeye to change the way doctors take blood samples. Microeye provides a continous sample from venus blood without removing whole blood. When coupled with Probe’s continumon it gives the clinician continous data showing trends and rate of change.
investment: £233,630 target: £499,968 pre-money valuation: £5,049,066
status: Funded
More Information
47%
CELLMED Medical EIS
Cellmed is an immuno-oncology company that are developing treatments for ovarian cancer.  Their lead product PROCURE a dendritic cell vaccine and they are now looking to expand the treatment to target solid tumors.    
investment: £520,294 target: £500,000 pre-money valuation: £2,400,232
status: Stretch
More Information
104%
YProTech provide a specialist service for the pharmaceutical, biotechnology (life sciences) and applied chemical sectors. They provide a fast and reliable delivery of laboratory scale chemistry development services.
investment: £234,438 target: £134,000 pre-money valuation: £1,354,889
status: Extended
More Information
175%
Prosperity House - 2x 2 Bed BTLs Housing and Property
These two high quality, two bedroom apartments have been completed as part of the first phase of development at Prosperity House. They have been provided by Prosperity at a signficant discount and have been taken up by an experienced LandLord who is also a CrowdLords member. The LandLord has a portfolio of 23 other properties in various locations around the country including one nearby in Nottingham. He has decided to offer Interim Equity for a period of 12 months after which time he will decide whether to sell or refinance the apartments. In return for their investment Investors enjoy a share of income and a share of any capital gain at the end of the investment term. With this investment the Income yield is paid quarterly and is projected to be 2.8% p.a. paid by way of Dividend, and the capital gain will be a share of 75% of the increase in vale, projected to combine to deliver a total return of 21.3%..
investment: £140,225 target: £143,800
status: Active
More Information
98%
Bivictrix Therapeutics Limited Medical EIS SEIS
BiVictriX Therapeutics is a pharmaceutical company that are developing ADC's (Antibody Drug Conjugates) in the field of Oncology. They have invented a strategy that improves ADC selectivity towards cancer cells.
investment: £451,506 target: £430,000 pre-money valuation: £4,347,778
status: Extended
More Information
105%
Redag Crop Protection Limited Catering, Food and Drink EIS
Redag Crop is an agrochemical discovery business focused on products that play a vital role in controlling the pests and diseases that threaten our global food supply. The growing population, expected to grow by 8 billion by 2020 and then 9 billion by 2050, will need more crops than the existing land can produce. Each hectare will need to produce 2.5 times as many crops as they do now. 
investment: £1,250,000 target: £1,250,000 pre-money valuation: £12,638,889
status: Extended
More Information
100%
Kings Mill Development Phase 2 - Interim Equity Housing and Property
An opportunity to invest in the development of a collection of stylish new homes consisting, in total, of 43x, 2 and 3 bed houses and 103x, 1 and 2 bed apartments.   This significant development by Prosperity will bring much needed housing stock to meet the demand from first time buyers as well as from the rental market. The development will be carried out in four phases and a proportion of each phase has been purchased by Prosperity to be sold onto investment buyers.   We are raising equity for the purchase of the site (Subject To Planning) in tranches linked to each Phase. Phase 2 will provide 17x, 2 bed houses and 3x, 3 bed houses, all to be completed within the first 18 months of the build program. All the 2 bed houses are pre-sold to Prosperity generating nearly £2m of sales revenue, and the 3 bed houses will be sold off-plan to local buyers.   The developer has secured the site and is contributing £300k of the total equity, with the remainder coming from CrowdLords Investors. In return for an investment in this Phase, holders of Redeemable Class C shares will receive 45.6% of their share of the projected profit which equates to around 39% of projected Phase 2 net profits, after tax. This will be paid as a capital gain when the shares are redeemed at a price of £1.30 per share, on or before the 28th February 2019.  
investment: £149,299 target: £333,300
status: Active
More Information
45%
 AskIf is platform that provides loan funding to small businesses. Each borrower has one or more relationship managers they can talk to. They are collecting data around social impact and are planning on monetising the data within their own business model and also to external stakeholders. AskIf will use the funding to expand referral partnership, increase the amount of their lending partners that are using the platform, make strong relationships to bring in new tech resource in house and bring in loan capital. 
investment: £668,753 target: £399,995 pre-money valuation: £3,001,323
status: Extended
More Information
167%
A juice concentrates company with the aim of selling healthier products, which have no added sugar or artificial ingredients. Delicious and healthy drinks can be made by adding Fiovana's many flavours to still or sparkling water. Fiovana's range is readily available from retailers, as well as a regular subscription from the company's website. Britvic has already £100,000.
investment: £190,000 target: £300,000 pre-money valuation: £1,276,458
status: Funded
More Information
63%
ADC Biotechnology Limited Technology EIS
ADC Biotechnology provides specialist drug manufacturing services based on its own patented Lock-Release™ processing technology, focused on a new wave of oncology therapeutics called antibody-drug conjugates (“ADCs”) being developed by pharmaceutical companies worldwide.
investment: £6,243,502 target: £6,000,000 pre-money valuation: £60,666,667
status: Extended
More Information
104%
Funnel Music is a Music Rights and distribution business, designed to harness the power of modern technology in the music industry. Funnel’s unique business model will disrupt the sector through introducing considerable cost savings to the creation and commercialisation of an artist through Funnel’s ‘Shared Outcome Model’ thus providing sustainable long-term revenues for itself and the artists it engages with.
investment: £85,000 target: £85,000 pre-money valuation: £859,444
status: Extended
More Information
100%
inflo AI Technology EIS
Companies can now engage with their online audience more effectively with the use of artificial intelligence. Inflo AI allows users to combine and collaborate on content in a single view, which is then seamlessly distributed and integrated into websites for ease of access and greater visibility for the end user.
investment: £380,000 target: £600,000 pre-money valuation: £3,655,319
status: Funded
More Information
63%
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph